AMH and ovarian cancer: A high-confidence finding, the anti-mullerian hormone receptor (AMHR2, MISIIR), which is a member of the TGFB receptor family of serine/threonine receptor kinases, is expressed in 6 human ovarian cancer cell lines [21], [22] in vitro treatment with MIS led to decreased colony formation consistent with the co-stimulatory effect we observed here: above median expression of AMHR2 leads to 10.4 months increased survival.